YOLFTbeta
AEON Biopharma, Inc.

AEON Biopharma, Inc.

AEON · AMEX · Healthcare / Biotechnology

0.153USD-0.01 (-3.59%)

Price History

Full chart

Market Stats

Previous Close0.1587
Open0.161
Day Range0.153 – 0.1699
52-Week Range0.177 – 1.45
Volume785.92K
Market Cap12.98M
P/E (TTM)0.00
Forward P/E1.16
EPS-4.49
Dividend Yield0.00%
Beta0.65
50-Day Avg0.2637
200-Day Avg0.7744

About

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Robert Bancroft
  • Employees8
  • Headquarters5 Park Plaza, Irvine, CA, United States, 92614, USA
  • Websitehttps://www.aeonbiopharma.com

Leadership

  • Mr. Robert BancroftPresident, CEO & Director · b. 1965
  • Mr. Alex WilsonChief Legal & Strategy Officer and Corporate Secretary · b. 1987
  • Dr. Chad K. Oh M.D.Chief Medical Officer · b. 1958
  • Mr. John A. Bencich M.B.A.Chief Financial Officer · b. 1977
  • Ms. Jennifer SyChief Accounting Officer · b. 1985

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.36M2.52M00-00
Growth (%)--24.99%-100.00%----
Cost of Revenue1.00K0----78.00K
Gross Profit3.36M2.52M-----78.00K
Gross Margin99.97%100.00%-----
Operating Expense57.32M18.91M----12.72M
Operating Income-53.97M-16.39M-65.85M-48.43M-348.09M72.98M-12.80M
Operating Margin-1607.57%-650.83%-----
EBITDA-47.49M-15.51M-36.88M-52.49M-52.74M-27.73M-16.22M
EBITDA Margin-1414.80%-616.08%-----
Net Income172.92M-32.91M-55.64M-52.56M-384.63M42.01M-39.22M
Net Income Margin5151.03%-1307.11%-----
R&D4.81M7.32M25.73M34.75M33.05M14.18M4.09M
R&D as % of Total Revenue143.40%290.67%-----
Interest Expense7.47M15.00K-----
Interest Expense % of Total Revenue222.52%0.60%-----

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets114.35M21.21M6.44M10.78M6.84M3.14M5.56M
Total Liabilities180.22M224.45M230.26M281.19M159.89M31.71M60.59M
Total Equity-67.15M-208.27M-234.94M-287.50M-153.04M-28.57M-55.03M
Cash6.32M20.17M5.13M9.75M5.16M13.00K3.01M
Total Debt29.95M72.16M86.89M131.53M278.00K12.96M35.74M
Net Debt23.63M51.99M81.76M121.79M-4.88M12.94M32.74M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-44.73M-9.46M-28.43M-35.58M-47.83M-20.29M-17.31M
Investing Cash Flow-117.29M-1.26M-170.00K-306.00K---4.00K
Financing Cash Flow73.21M24.57M13.56M40.51M14.00M15.15M20.30M
Capital Expenditure1.69M170.00K170.00K306.00K004.00K
Free Cash Flow-46.42M-9.46M-28.60M-35.89M-47.83M-20.29M-17.31M
Dividends Paid83.91M------
FCF to OCF103.79%100.00%100.60%100.86%100.00%100.00%100.02%
Dividend Paid to FCF-180.76%------

Earnings

Report DateJun 30, 2021Oct 4, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022May 31, 2023Aug 30, 2023Nov 13, 2023Mar 29, 2024May 14, 2024Aug 12, 2024Nov 13, 2024Mar 24, 2025May 14, 2025Aug 12, 2025Nov 14, 2025Dec 31, 2025May 14, 2026Aug 12, 2026Nov 13, 2026
EPS Estimate-0.00--------38.16-28.80-0.31-13.68-11.52---0.35-0.43-0.20-0.44-0.33-0.07
EPS Actual-8.40-1.660.525.793.903.430.19-1.40-31.8882.80-51.12-0.285.34-11.523.472.28-0.60-0.39-3.72-0.25-0.02-
Surprise---------316.98%-77.50%9.68%139.04%0.00%---71.43%9.30%-1714.63%43.18%93.94%-
Timing---------Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours--After-hoursPre-market-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap12.98M
Enterprise Value12.41M
Trailing P/E0.00
Forward P/E1.16
Price / Sales97.16
Price / Book0.00
EPS-4.49
Book Value-0.584
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-19.82M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets-141.53%
Shares Outstanding49.88M
Shares Float24.01M
Beta0.65
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 1.53
  • Strong Buy
    1

Stock Splits

  • Feb 26, 20251:72